Fig. 2.
Treatment with metformin is associated with a healthier biomarker profile in patients with prodromal Alzheimer’s disease. A Biplot obtained from a principal component analysis performed on 455 MCIAD subjects. Black dots represent patients receiving metformin. B Box plots indicating the mean value of principal components 1 and 2 for MCIAD-metformin patients (n = 31). *p < 0.05; ns, non-significant differences (one-sample t-test compared with a theoretical mean of zero). C Standardized coefficients obtained for each variable included in the principal component analysis